Low tumour content not only impedes detection of low allele frequency somatic mutations but also affects the correct assessment of copy number variations as these may be diluted into the normal copy number profile of non‐tumour cells in the samples; this is particularly relevant to identify patients with intragenic or homozygous BRCA2 deletions. The gene discussed is BRCA2; the disease is neoplasm.